If you or someone you love is living with stiff person syndrome — or is in the frightening limbo of progressive stiffness and startle-triggered spasms with an anti-GAD65 antibody result pending — you have likely encountered both serious neurology and a flood of irresponsible "natural cure" claims. This page is deliberately not the latter. We are going to walk through the genuine biology of SPS: the GAD65 enzyme and the GABA it makes, the loss of inhibition in spinal cord interneurons that locks agonist and antagonist muscles into co-contraction, the antibodies and the variants behind them, and the specific, mechanism-level points where sea moss's minerals plausibly intersect with neuroprotection and inhibitory synapse stability. We will be equally clear, and repeatedly so, about the high-dose benzodiazepines and baclofen, the IVIG and plasmapheresis and rituximab, the urgent cancer screening some patients need, and everything sea moss cannot do. Honesty about limits is the entire point.

1. What Is Stiff Person Syndrome?

Stiff person syndrome (SPS), once called stiff man syndrome, is a rare neuroimmunological disorder — affecting on the order of one to two people per million — characterized by progressive, fluctuating muscle rigidity and superimposed, often agonizing, muscle spasms. The rigidity classically begins in the axial muscles of the trunk and abdomen and the proximal limbs, producing a stiff, board-like posture, an exaggerated curve of the lower back (lumbar hyperlordosis), and a characteristically wooden, slow, and cautious gait. Layered on top of this background stiffness are episodic spasms that can be triggered by sudden noise, light touch, emotional stress, or being startled, and that can be powerful enough to fracture bone or hurl a person to the ground.

The defining problem in SPS is a loss of inhibition in the central nervous system. Normally, the spinal cord and brain are full of inhibitory circuits that keep muscle tone in check and ensure that when one muscle contracts, its opposing muscle relaxes. In SPS, that inhibitory brake fails. The result is continuous, involuntary co-contraction of agonist and antagonist muscles — the muscle that bends a joint and the muscle that straightens it firing at the same time, fighting each other and locking the body rigid. Understanding why that brake fails — and it comes down to a single neurotransmitter, GABA, and the enzyme that makes it — is the through-line of this entire page.

Why it is so often missed

Because the early symptoms — stiffness, back pain, anxiety, a fear of falling — are common and nonspecific, SPS is frequently misdiagnosed for years as a musculoskeletal problem, a functional or psychogenic disorder, anxiety, or Parkinson's disease. The episodic spasms triggered by emotion and the prominent anxiety can wrongly cement a purely psychiatric label. In reality the anxiety in SPS is, in large part, neurological — the same loss of GABAergic inhibition that stiffens muscles also dysregulates the brain circuits that govern fear and startle. Recognizing SPS as a treatable autoimmune disease, rather than a psychological one, is often the turning point in a patient's care.

2. The Pathophysiology: How the GABA Brake Fails

To understand SPS you have to understand one neurotransmitter and one enzyme. The neurotransmitter is GABA (gamma-aminobutyric acid), the principal inhibitory signal in the brain and spinal cord — the chemical "off switch" that quiets neurons. The enzyme is glutamic acid decarboxylase, which exists in two forms, GAD65 and GAD67. GAD65 is the form concentrated at nerve terminals, and its job is to convert the excitatory neurotransmitter glutamate into the inhibitory neurotransmitter GABA. In other words, GAD65 sits at the exact switch point that turns "go" into "stop."

Anti-GAD65 antibodies and the loss of GABA

In the great majority of classic SPS, patients produce autoantibodies against GAD65. By interfering with this glutamate-to-GABA conversion and with the packaging and release of GABA, anti-GAD65 antibodies reduce the brain's and spinal cord's supply of inhibitory signaling. Less GABA means less inhibition; less inhibition means neurons that should be quiet stay active. The result is the central paradox of SPS: a nervous system that has lost its ability to say "stop," leaving muscles locked on.

Spinal cord interneurons and muscle co-contraction

The most consequential site of this failure is the spinal cord, where small inhibitory interneurons normally coordinate movement. Two of these are central. Renshaw cells provide recurrent inhibition that dampens motor neuron firing, and Ia inhibitory interneurons provide reciprocal inhibition — the circuit that relaxes the antagonist muscle whenever an agonist contracts. When GABAergic (and the related glycinergic) inhibition of these interneurons collapses, reciprocal inhibition fails. The agonist and antagonist contract simultaneously, the joint stiffens, and the EMG shows the hallmark of SPS: continuous motor unit activity in muscles that should be at rest. This is also why the rigidity is worst in the trunk — the axial muscles are governed by these spinal circuits and are densely co-innervated.

Brain involvement and the startle / spasm trigger

SPS is not only a spinal disease. The loss of GABAergic inhibition also affects brainstem and cortical circuits, which is why ordinary stimuli — a slammed door, an unexpected touch, a wave of anxiety — can unleash a violent, generalized spasm. The exaggerated startle response, sometimes called hyperekplexia, reflects this brain-level disinhibition, as does the prominent task-specific and phobic anxiety many patients describe. The same circuits that should filter and dampen sensory and emotional input have lost their brake.

Other antibodies and the inhibitory synapse

Anti-GAD65 is the most common antibody, but SPS-spectrum disorders involve several others, each pointing at the same theme — a damaged inhibitory synapse. Anti-amphiphysin antibodies target a protein involved in synaptic vesicle recycling and define a paraneoplastic variant linked to breast cancer. Anti-glycine receptor (anti-GlyR) antibodies attack the glycine receptor, the other major inhibitory receptor in the spinal cord and brainstem, and are characteristic of the most severe variant, PERM. Anti-DPPX antibodies, which affect potassium-channel regulation and neuronal excitability, are associated with an SPS-overlap presentation that often includes prominent gut symptoms. Despite different molecular targets, all converge on the same functional endpoint: too little inhibition.

3. The SPS Spectrum: Variants Compared

Stiff person syndrome is best understood not as one disease but as a spectrum of related disorders that share the loss-of-inhibition theme but differ in distribution, severity, antibody, and prognosis. Knowing which variant a patient has shapes the entire treatment plan — especially whether an urgent cancer search is needed.

The practical message of this table is that the word "stiff person syndrome" can describe anything from a single rigid leg to a fulminant brainstem encephalomyelitis. That is why a precise variant diagnosis — built from the antibody panel, the distribution of symptoms, and a malignancy workup — determines prognosis and treatment far more than the umbrella label.

4. Clinical Presentation: What SPS Looks Like

The clinical picture of stiff person syndrome is distinctive once recognized, and it follows directly from the loss of inhibition described above.

• Progressive axial rigidity: stiffness that begins in the trunk and abdomen and spreads, producing the characteristic lumbar hyperlordosis (an exaggerated arch of the lower back) and a hard, board-like abdominal wall.
• Painful episodic spasms: sudden, severe muscle spasms triggered by noise, touch, emotion, or startle; they can be powerful enough to cause falls, joint dislocations, or fractures, and are often acutely painful.
• Falls without protection: because the body is rigid, patients frequently fall like a statue — unable to extend an arm to catch themselves — leading to disproportionate injuries.
• Hyperekplexia: an exaggerated, sustained startle response to stimuli that would barely register in others.
• Gait disorder: a slow, stiff, wide-based, cautious walk; some patients become functionally housebound by a profound fear of triggering a spasm in open spaces.
• Autonomic dysfunction: episodes of sweating, blood pressure surges, tachycardia, and pupillary changes, most prominent during severe spasms and in PERM, where dysautonomia can be dangerous.
• Anxiety and depression: prominent and partly neurological in origin (GABAergic disinhibition), often with task-specific phobias such as a fear of crossing the street, reinforced by the real risk of spasm-induced falls.

A clinically important detail is that the rigidity in SPS classically improves during sleep and under general anesthesia and is partially relieved by benzodiazepines — features that distinguish it from many structural causes of stiffness and that themselves point to a GABAergic mechanism, since these are exactly the conditions under which GABA signaling is augmented or motor drive is suppressed.

5. Diagnosis: Antibodies, EMG, and the Titer That Matters

The diagnosis of SPS rests on a combination of the clinical picture, autoantibody testing, electromyography, and the careful exclusion of mimics and of paraneoplastic disease.

Anti-GAD65 titer: SPS versus type 1 diabetes

Anti-GAD65 antibodies are the cornerstone test, but there is a crucial nuance: the titer (the level) matters as much as the presence. The same antibody appears in type 1 diabetes, where it targets GAD65 in the pancreatic beta cell, but there it is usually present at low titer. In SPS, anti-GAD65 is typically present at very high titer — often cited as greater than roughly 2,000 IU/mL or in the tens of thousands — reflecting an intense, CNS-directed autoimmune response. Measuring anti-GAD65 in the cerebrospinal fluid (CSF), and demonstrating that it is being produced intrathecally (within the CNS) rather than merely leaking in from blood, further strengthens the diagnosis.

Lumbar EMG and continuous motor unit activity

Electromyography of the paraspinal (lumbar) muscles provides objective confirmation. The hallmark is continuous motor unit activity — ongoing electrical firing in muscles that should be electrically silent at rest, with simultaneous activity in agonist and antagonist muscles. This co-contraction signature, which abolishes with diazepam, is highly supportive of SPS and helps distinguish it from other causes of stiffness.

Excluding paraneoplastic disease and mimics

Diagnosis is not complete without considering the paraneoplastic differential. Anti-amphiphysin and anti-DPPX should be tested, and in the right context a malignancy workup pursued (see the red flags below). The differential also includes spasticity from structural spinal disease, dystonia, neuromyotonia, tetanus, hereditary hyperekplexia, and functional neurological disorder — which is why a neurologist experienced with SPS, rather than a single lab result in isolation, should anchor the diagnosis.

6. Treatment: What Actually Controls SPS

SPS treatment has two arms that are used together: symptomatic therapy that boosts the remaining GABA signal to relax muscles, and immunotherapy that targets the underlying autoimmune process. These are the interventions that change the course of the disease.

GABAergic symptomatic therapy

• High-dose diazepam: the long-standing first-line drug. A benzodiazepine, it potentiates the GABA-A receptor, amplifying whatever inhibitory signaling remains. Doses in SPS are often far higher than typical, titrated against rigidity and spasms.
• Baclofen: a GABA-B receptor agonist that reduces spasticity and spasms. For severe, refractory rigidity, an intrathecal baclofen pump — delivering the drug directly into the CSF — can achieve control at far lower doses with fewer systemic side effects.
• Clonazepam: another benzodiazepine, useful for spasms and the nocturnal and anxiety components.
• Tizanidine and other agents: adjuncts for muscle tone; some patients also use gabapentinoids or, cautiously, other muscle relaxants under specialist guidance.

Immunotherapy

• IVIG (intravenous immunoglobulin): the immunotherapy with the strongest controlled-trial evidence in SPS and widely regarded as the gold-standard immune treatment; it can meaningfully reduce stiffness and spasms.
• Plasmapheresis (plasma exchange): physically removes circulating autoantibodies; used especially in severe or rapidly progressive disease, including PERM.
• Rituximab: a B-cell-depleting monoclonal antibody used for refractory disease, aiming to reduce ongoing autoantibody production.
• Corticosteroids and other immunosuppressants: used in selected cases to dampen the autoimmune response, weighed against their risks.

Trigger avoidance and physical/aquatic therapy

Because spasms are provoked by noise, touch, startle, and emotional stress, a deliberate trigger-avoidance protocol (covered below) is part of daily management. Physical therapy is valuable but must be gentle and specific; aggressive stretching can provoke spasms. Aquatic (swimming) therapy is especially favored because the buoyancy and warmth of water reduce fall risk and allow gentle, supported movement — also detailed below.

7. Fucoidan: Neuroinflammation and the Autoantibody Drive

Fucoidan is a sulfated polysaccharide concentrated in sea moss and related seaweeds, and it is one of the more mechanistically interesting compounds on this page because its known activities map onto the inflammatory side of SPS biology.

NF-kB suppression and neuroinflammation

Fucoidan has been shown in preclinical research to downregulate NF-kB, the master transcription factor that drives inflammatory gene expression. In the nervous system, activated microglia and astrocytes signal heavily through NF-kB, releasing inflammatory cytokines such as IL-6 and TNF-alpha that can disturb synaptic function. In SPS, where antibody-driven inflammation acts on inhibitory circuits, dampening this pathway is a plausible anti-inflammatory touchpoint — though it has never been tested in human SPS.

B-cells, BAFF/APRIL, and autoantibody production

The autoantibodies that define SPS — anti-GAD65, anti-amphiphysin, anti-GlyR — are made by B-cells and plasma cells sustained by survival factors such as BAFF and APRIL. This is precisely why rituximab, which depletes B-cells, is used in refractory disease. Fucoidan's broad immunomodulatory profile includes effects on B-cell signaling in laboratory models, which is the same general leverage point — tempering autoantibody production — at a far gentler, purely nutritional scale. The honest framing: this is a long-game, preclinical possibility, not a demonstrated reduction in anti-GAD65 levels in patients.

8. Omega-3 DHA: Brain, Myelin, and the Resolution of Inflammation

Sea moss supplies marine omega-3 fatty acids, and these matter for SPS in two ways: as structural material for the nervous system and as the raw material for resolving inflammation.

DHA as a structural brain and myelin component

Docosahexaenoic acid (DHA) is a major structural component of the brain and of neuronal and myelin membranes. The fluidity and function of synaptic membranes — including the inhibitory synapses central to SPS — depend on an adequate supply of DHA. A nervous system under autoimmune stress is a nervous system with a heightened need for the building blocks of membrane repair and maintenance, and DHA is foremost among them.

Specialized pro-resolving mediators and neuroprotection

Beyond structure, DHA and EPA are the precursors to specialized pro-resolving mediators — resolvins, protectins (including neuroprotectin D1, NPD1), and maresins. These molecules do not merely blunt inflammation; they actively resolve it, helping switch off microglial activation and protect neurons under inflammatory stress. In a disease sustained by chronic neuroinflammation, supporting the body's resolution machinery is a mechanistically sensible, if supportive, goal. Omega-3 intake is also relevant to the mood symptoms of SPS, given DHA's broader role in neuronal and affective function — though, again, this is supportive terrain, not a treatment for the disinhibition that drives the anxiety.

9. Selenium: GPx4, Ferroptosis, and Neuronal Protection

Selenium is the cofactor for a family of antioxidant selenoproteins, and its most striking relevance to SPS is the protection of neurons against oxidative and ferroptotic injury.

GPx4 and ferroptosis

The key selenoenzyme is glutathione peroxidase 4 (GPx4), which prevents ferroptosis — a form of cell death driven by uncontrolled lipid peroxidation of membranes. Neurons, with their large lipid-rich membranes and high metabolic demand, are especially vulnerable to ferroptosis, and chronic neuroinflammation raises the oxidative burden further. Adequate selenium feeds GPx4, supporting the defense that keeps neuronal membranes from peroxidizing under inflammatory stress.

Broader selenoenzyme support

Selenium also powers thioredoxin reductase and other glutathione peroxidases that maintain the redox environment neurons depend on. While none of this targets the anti-GAD65 process directly, a well-supplied antioxidant defense is part of a nervous system better equipped to withstand the oxidative side of autoimmune injury. This is nutritional terrain — not a way to stop the antibody attack.

10. Zinc: GABA-A Receptor Modulation and Inhibitory Synapse Stability

Of all the minerals in sea moss, zinc has perhaps the most intriguing direct line to the inhibitory synapse that fails in SPS.

Zinc is concentrated in synaptic vesicles in many parts of the brain and acts as a neuromodulator at the GABA-A receptor — the very receptor that diazepam potentiates. Zinc and the related signaling around inhibitory synapses contribute to the assembly and stabilization of the inhibitory synapse, including the scaffolding (such as gephyrin) that clusters inhibitory receptors at the synapse. In a disease defined by failing inhibitory synapses, maintaining adequate zinc status is a mechanistically reasonable supportive goal: zinc deficiency can impair inhibitory neurotransmission, and correcting a deficiency supports the substrate on which the GABA system runs.

The careful framing matters here: zinc's modulation of the GABA-A receptor is complex and concentration-dependent — this is about supporting normal zinc status, not about megadosing zinc to "boost GABA." Sea moss contributes zinc as part of its mineral profile, and the goal is sufficiency, not pharmacology.

11. Iodine and the SPS–Thyroid Connection

Iodine is the mineral sea moss is best known for, and it is relevant to SPS through a specific autoimmune connection. SPS, and anti-GAD65 autoimmunity generally, clusters with autoimmune thyroid disease — the same patients who carry anti-GAD65 frequently also carry thyroid autoantibodies and have Hashimoto's thyroiditis or Graves' disease. Thyroid hormone, which requires iodine, is essential for normal neuromuscular function and brain function, so thyroid status is part of the overall picture in an SPS patient.

12. The Mechanisms at a Glance

Pulling the mineral story together, here are the named, plausible — and strictly supportive — touchpoints between sea moss's bioactives and SPS biology.

13. The Baclofen Pump: Candidacy for Severe Disease

For patients whose rigidity and spasms are severe and not adequately controlled by oral medication, an intrathecal baclofen pump can be transformative. A small programmable pump is implanted under the skin of the abdomen with a catheter delivering baclofen directly into the cerebrospinal fluid around the spinal cord, achieving high local concentrations at the inhibitory circuits while sparing the body the heavy side effects of equivalent oral doses.

Candidacy is a specialist decision, but the general profile of a person considered for an intrathecal baclofen pump includes:

• Severe, disabling rigidity or spasms that significantly impair function or cause dangerous falls.
• Inadequate response to, or intolerable side effects from, oral therapy — high-dose oral baclofen or benzodiazepines causing excessive sedation or other limiting effects.
• A positive response to a screening intrathecal baclofen trial, in which a test dose demonstrates meaningful reduction in rigidity before committing to implantation.
• Adequate body habitus and absence of contraindications to the implant, with the ability to attend regular pump refills and follow-up.
• Realistic goals and reliable follow-up, since pump malfunction or abrupt baclofen withdrawal is a medical emergency.

A baclofen pump is a serious, long-term commitment with its own risks, but for the right patient with refractory SPS it can restore mobility and dignity that oral drugs could not. Sea moss has no relationship to this decision other than the general nutritional support of a person undergoing major treatment — and even then, only with the team's awareness, given fucoidan's mild anticoagulant properties around any surgical procedure.

14. The Trigger-Avoidance Protocol

Because spasms in SPS are provoked by specific stimuli, deliberately reducing exposure to triggers is a practical, daily part of living with the disease — one that genuinely reduces the frequency of dangerous episodes. A trigger-avoidance protocol typically includes:

• Sudden noise: minimize startling sounds — alarms, slamming doors, loud unexpected noises. Some patients use predictable, gentle alerts and warn household members and coworkers.
• Unexpected touch: ask others to approach from the front and announce themselves; avoid being startled by a touch from behind.
• Emotional stress: because emotion and anxiety are potent triggers (and are themselves amplified by the neurological disinhibition), stress-reduction practices, treating the anxiety component, and pacing of demanding situations all help.
• Startle and rushing: build in extra time so that hurrying, fright, and sudden urgency — all of which can precipitate a spasm — are minimized.
• Cold and physical stressors: sudden cold and overexertion can aggravate stiffness for some; warmth and gentle pacing are generally better tolerated.
• Environmental adaptation: fall-proofing the home, using assistive devices, and avoiding open, exposed spaces that provoke phobic anxiety and the spasms that fear can trigger.

None of this replaces medication, but combined with GABAergic drugs it can meaningfully lower the burden of acute, injurious spasms — a quality-of-life intervention that costs nothing and risks nothing.

15. Aquatic Therapy: Why Water Helps

Physical therapy in SPS is a balancing act — movement is valuable, but aggressive stretching can provoke painful spasms. This is exactly why aquatic (swimming) therapy is so frequently recommended as the form of exercise best suited to the disease. The benefits of working in warm water include:

• Buoyancy reduces fall risk: water supports the body, so a person who falls "like a statue" on land is far safer moving in a pool, where the consequences of a spasm-induced loss of balance are cushioned.
• Warmth relaxes muscles: warm water tends to ease rigidity and is generally better tolerated than cold, which can aggravate stiffness.
• Gentle, supported range of motion: buoyancy allows joints to move through a range that would be difficult or spasm-provoking against gravity on land.
• Cardiovascular and conditioning benefit: aquatic exercise maintains fitness and muscle conditioning without the high-impact stress and fall risk of land-based exercise.
• Reduced fear: the safety of the water can ease the phobic anxiety that itself triggers spasms, creating a virtuous cycle in which calmer movement is possible.

Aquatic therapy should still be supervised and tailored, and water temperature kept comfortable, but for many people with SPS it is the single most sustainable form of beneficial movement.

16. Managing Coexisting Type 1 Diabetes and SPS

Because SPS and type 1 diabetes share the anti-GAD65 antibody — the same autoimmunity aimed at GAD65 in neurons in one disease and in pancreatic beta cells in the other — a meaningful number of people live with both, or with SPS plus another organ-specific autoimmune condition such as thyroid disease or pernicious anemia. Managing the dual autoimmunity requires a few specific considerations:

• Coordinated specialist care: a neurologist for SPS and an endocrinologist for diabetes (and thyroid), communicating, since treatments and monitoring overlap.
• Steroid–glucose interactions: if corticosteroids are used as immunotherapy for SPS, they raise blood glucose and complicate diabetes control — a reason teams often favor IVIG or steroid-sparing approaches in this population.
• Screening the cluster: a patient with anti-GAD65 SPS warrants screening for the conditions that travel with it — type 1 diabetes, autoimmune thyroid disease, and pernicious anemia — because catching them early matters.
• Iodine and thyroid vigilance: the same iodine caution applies with redoubled force in someone who already carries multiple autoimmune diagnoses; thyroid status should be known and monitored before any iodine-rich supplement is added.
• Vitamin B12 and pernicious anemia: because pernicious anemia (autoimmune gastritis impairing B12 absorption) clusters here and B12 deficiency causes its own neurological harm, B12 status deserves attention in the SPS patient.

For someone living with both SPS and type 1 diabetes, sea moss is a supplement to be approached with particular care: its iodine load must be reconciled with thyroid status, its mineral content discussed against the whole medication list, and it must never become a reason to relax the tight, evidence-based control that both diseases demand.

17. What Sea Moss Cannot Do

This section is the heart of an honest page. Stiff person syndrome is a serious autoimmune neurological disease, and clarity about the limits of a sea vegetable is not a disclaimer to skim — it is the truth that protects you.

• Sea moss cannot restore GABAergic inhibition. The core defect in SPS is too little GABA-mediated inhibition because anti-GAD65 antibodies impair the enzyme that makes GABA. Only GABA-enhancing drugs (diazepam, baclofen, clonazepam) can boost that signal pharmacologically. No food does this.
• Sea moss cannot lower anti-GAD65 antibodies in any proven way. Reducing the autoimmune attack requires immunotherapy — IVIG, plasmapheresis, rituximab. Fucoidan's effects on immune signaling are preclinical and gentle and have never been shown to reduce anti-GAD65 in patients.
• Sea moss cannot prevent or treat the dangerous spasms. The startle-triggered spasms that fracture bones and cause falls are controlled by medication and trigger avoidance, not by minerals.
• Sea moss cannot substitute for the paraneoplastic cancer workup. If anti-amphiphysin antibodies or red flags point to a tumor, finding and treating that cancer is the priority — a medical emergency in which sea moss has no role.
• Sea moss cannot replace physical and aquatic therapy or the structured trigger-avoidance and fall-prevention strategies that reduce injury.
• Sea moss can carry real risks if used carelessly — its high iodine content can destabilize the coexisting thyroid autoimmunity common in SPS, and its mild anticoagulant fucoidan matters around plasma exchange and surgery. This is why medical clearance is mandatory, not optional.

What sea moss can offer is supportive nutritional terrain — minerals and bioactives that, on mechanistic grounds, may support neuronal resilience, the resolution of inflammation, and the substrate of inhibitory synapses — layered carefully on top of real treatment. That is a meaningful but modest role, and stating it honestly is the entire point of this page.

18. How to Use Sea Moss Supportively (With Your Team)

If your neurology and endocrinology teams agree it is appropriate, sea moss can be incorporated as a nutrient-dense whole food alongside — never instead of — your prescribed care:

• Clear it first. Given the iodine–thyroid interaction and the anticoagulant note, confirm with the team managing your SPS, immunotherapy, and thyroid before starting.
• Start low and consistent. A typical approach is 1 to 2 tablespoons of gel daily, taken with a fat-containing meal to support absorption of the fat-soluble omega-3s.
• Monitor thyroid function. Have thyroid hormones and antibodies checked given the SPS–thyroid overlap, and revisit them after starting an iodine-rich food.
• Judge by labs and exams, not by feel. SPS is tracked by neurological examination, EMG, anti-GAD65 titers, and your specialist's assessment — not by how a supplement makes you feel.
• Give it time and keep perspective. Any nutritional support is cumulative and slow, working over weeks to months if it does anything noticeable at all, and is always secondary to the medication and immunotherapy that control the disease.

19. Frequently Asked Questions